Leelahavanichkul A, Somparn P, Bootprapan T, Tu H, Tangtanatakul P, Nuengjumnong R, Worasilchai N, Tiranathanagul K, Eiam-Ong S, Levine M, Chinampon A, Srisawat N. High-dose ascorbate with low-dose amphotericin B attenuates severity of disease in a model of the reappearance of candidemia during sepsis in the mouse.
immune response in sepsis may present as a hyperimmune characteristic with a rapid natural course of disease and/or an immunosuppression phase responsible for nosocomial infection (55, 62) . Candidiasis, especially resulting from Candida albicans, is one of the leading worldwide nosocomial infections occurring after the onset of sepsis (30, 49) . The mortality rate of patients with postsepsis systemic candidiasis is more than 50%, with more than 25% of cases of candidiasis occurring in patients who had developed sepsis (17, 22) . Although the incidences of infection from other fungal species are increasing in patients in the intensive care unit, C. albicans still remains the leading cause of nosocomial fungal infection (22, 48, 51) . The increasing prevalence of nosocomial fungal infection in cases of sepsis may be due to the growing use of broad-spectrum antibiotics coupled with the advancement of intensive care supports (8, 29, 37, 43, 59) .
Amphotericin B (Ampho B) is a traditional broad-spectrum, dose-dependent fungicidal drug, which is a pore-forming agent that acts though ergosterol inhibition. Ampho B, unfortunately, has substantial dose-dependent nephrotoxicity, and liposomal amphotericin B is expensive (11) . If Ampho B can be used at a lower dose in combination with another agent, perhaps nephrotoxicity and cost will be reduced. When given intravenously as a pharmacological agent, ascorbate (ascorbic acid or vitamin C) demonstrates antineoplastic actions via the generation of extracellular hydrogen peroxide and downstream reactive oxygen species (ROS) (5-7, 37, 38) . ROS formed in the presence of pharmacological ascorbate are less toxic to the host tissue, but are very toxic to cancer cells in vitro and in vivo. We hypothesized that extracellular hydrogen peroxide generated by pharmacological ascorbate could enter the fungal cell wall, which is injured or made vulnerable by the fungicidal poreforming agent and enhanced antifungal therapeutic effectiveness (4 -7) . It should be noted that lower doses of ascorbate, given as a drug, may attenuate bacterial sepsis via additional mechanisms (1, 58, (63) (64) (65) 67) . If ascorbate demonstrates actions that support antibacterial and antifungal activities, then ascorbate in combination with Ampho B may be an effective combined therapy.
To study ascorbate in combination with antifungal agents, an animal model system is necessary. The available model for Candida infection, characterized by Candida injection after sepsis (9), may not reflect Candida infections in humans, which mostly resulted from endogenous sources (50) . As a result, we developed a new sepsis-induced candidemia reappearance model that is characterized by the reactivation of an exogenous Candida administration prior to the onset of sepsis. We used this new system to test Ampho B administered alone and in combination with pharmacological ascorbate.
METHODS

C. albicans Preparation, Characterization, and Germ Tube Test
C. albicans was isolated from blood samples (Mycology Unit, King Chulalongkorn Memorial Hospital), identified by morphology together with the API 20C AUX yeast identification kit (Biomuriex, Lyon, France), and stored in Sabouraud dextrose agar (SDA) (Thermo Scientific, Hampshire, UK) at Ϫ80°C. Before conducting all of the experiments, C. albicans was subcultured in SDA at 35°C for 24 h. The characteristics of the clinically isolated C. albicans were demonstrated by the minimal inhibitory concentration (MIC) ( Table 1) and 50% lethal dose (LD 50). MIC analysis followed a standard protocol (43) , with all reagents purchased from Sigma-Aldrich (St. Louis, MO). The Clinical Laboratory Standard Institute recommended strains Candida krusei American Type Culture Collection (ATCC) 6258 and Candida parapsilosis ATCC 22019 were used for quality assurance. The LD 50 of selected C. albicans was 4 ϫ 10 5 blastospores as counted by hemocytometer (Bright-Line, Denver, CO), which was equal to the value measured by a spectrophotometer (ELϫ808 absorbance reader; BioTek, Shoreline, WA) by the optical density at 630 nm at 0.45 (OD 630 nm at 0.45). The procedure for LD 50 was described in detail in the animal section below. For the germ tube test, 300 blastospores of C. albicans, as determined by hemocytometer, were placed in 50 l of serum from a septic mouse (24 h after CLP) or serum from a sham mouse, incubated at 37°C for 3 h, then counted by hemocytometer. The percentage of the ratio of blastospores with germ tube formation to total blastospores was calculated.
Animal and Animal Models
The U.S. National Institutes of Health (NIH) criteria and protocols for the use and treatment of laboratory animals were followed (NIH publication protocols no. 85-23, revised 1985) . Male, 8 -10-wk old BalB/C mice (National Laboratory Animal Center, Nakornpathom, Thailand) were used. The animal protocols were approved by the Institutional Animal Care and Use Committee of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. All procedures were performed under isoflurane anesthesia.
Candida albicans injection model. Resuspended C. albicans in normal saline solution (NSS) adjusted into different doses of optical density at 630 nm in the same volume of each preparation (100 l) was injected through the tail vein. The LD 50 was extrapolated from the correlation equation of the graph of the 7-day mortality of mice, which was injected with C. albicans in different OD 630-nm doses (0.8, 0.6, 0.4, 0.2, and 0.1). The Candida dose with 50% mortality rate was calculated and identified as LD 50. Cecal ligation and puncture sepsis model. The cecal ligation and puncture (CLP) procedure was described in detail previously (34) , with some modifications. Briefly, the cecum was ligated at 12 mm from the cecal tip and punctured twice with a 23-gauge needle, leaving a small amount of fecal material exposed. The abdominal incision was closed in two layers with 6-0 nylon sutures. Antibiotic (imipenem/cilastatin 7 mg/kg in 0.3 ml NSS) was administered subcutaneously at 3 h and 8 h after CLP for 24-h end-point experiments. Additional antibiotic doses were administered at days 2, 4, and 6 after operation for 7-day survival experiments (Fig. 1) .
A model of reappearance of candidemia during sepsis (candidaϩCLP). One hundred microliters of C. albicans with the dose of OD 630 nm at 0.3 (ϳ2 ϫ 10 5 blastospores) or reciprocal NSS was injected through the tail vein at the Ϫ6 h time point (Fig. 1 ). Then at 0 h, the CLP operation or sham laparotomy was performed. The schedule of antibiotic administration was demonstrated in Fig. 1 . In parallel, a reciprocal volume of NSS was injected in the sham group. Blood was collected through the right retroorbital plexus under (Fig. 1) . The ascorbate level after the administration on day 2 could not reach the therapeutic level, as defined by serum ascorbate more than 10 mM (data not shown).
Polymorphonuclear Cell Count, Blood Chemistry, and Cytokine Concentrations
A volume of 15 l of blood was mixed with 250 l of 3% acetic acid, a hemolytic solution, and the total number of leukocytes was counted with a hemocytometer. Simultaneously, 10 l of blood was smeared on a glass slide for Wright stain and counted with ϫ100 magnification in 100 fields to determine the percentage of polymorphonuclear cells (PMN). The total number of PMN was calculated by total leukocyte count from hemocytometer multiplied by the percentage of PMN from the Wright stain glass slide. Serum ascorbate (Asc) and alanine transaminase (ALT) were measured with colorimetric detection by ascorbic acid assay (BioAssay U.S. Biological, Salem, MS) and ALT assay (DiaSys Diagnostic Systems, Holzheim, Germany), respectively. Serum creatinine (Scr) was measured by HPLC (32) (33) (34) . Serum TNF-␣, IL-6, IL-10, and IL-17 were determined by the Luminex xMap-based multiplex technology MILLIPLEX MAP (multianalyte panels) 4-plex cytokine kit (Millipore, Billerica, MA), according to the manufacturer's recommended procedure.
Microorganism Burdens in Blood, Peritoneal Fluid, and Internal Organs
Blood and peritoneal fluid in serial volume was immediately diluted in PBS, plated in SDA for 24 h at 35°C for fungal colony counting, and reciprocally placed in blood agar (Oxoid, Hampshire, UK) for 24 h at 37°C for bacterial colony counting. Internal organs were washed twice in PBS, weighed, homogenized, diluted in PBS, and incubated in SDA. The colony count in SDA after 24 h at 35°C was defined as the C. albicans burden. Moreover, to test whether there was C. albicans in feces and gastrointestinal tissues of mice without a preconditioning Candida injection, the different amounts of fecal contents were collected. Serial dilutions of gastrointestinal contents and tissue from cecum, colon, and recto-sigmoid area were collected from normal mice and septic mice at 24 h after CLP. Feces, wellmixed in PBS, and tissues were plated directly in SDA with 0.1% chloramphenicol (Bio-Rad, Hercules, CA), Sabouraud dextrose broth (SDB), and SDB with 0.05 g/l chloramphenicol (Sigma-Aldrich).
Organ Histology
Tissue was fixed in 10% formalin and embedded in paraffin; 4-m sections were stained with periodic acid-Schiff reagent. Kidney damage was defined as tubular epithelial swelling, loss of brush border, and vacuolar degeneration. The degree of kidney damage was estimated at ϫ200 magnification using 10 randomly selected fields, according to the following criteria: 0, normal; 1, area of damage Ͻ25% of tubules; 2, damage involving 25-50% of tubules; 3, damage involving 50 -75% of tubules; and 4, 75-100% of the area being affected (35) . Spleen damage was determined by counting the number of vacuole-like areas and groups of necrotic and apoptotic cells (44) in the white pulp of the spleen at ϫ400 magnification.
In Vitro Experiment for the Synergistic Effect of Ascorbate and Amphotericin B
One hundred microliters C. albicans in the dose of OD 630 nm at 0.7 diluted in Rose Park Memorial Institute (RPMI) 1640 was put into a 96-well microplate. Ampho B dissolved in dimethyl sulfoxide (DMSO) to a concentration of 125 ng/ml, 10 times lower than the MIC (Table 1) , with serial concentrations of ascorbate (5-40 mM) adjusted to the neutral pH (pH 7) were mixed into each well. RPMI was added, as needed, to fully and equally fill each well. OD 630 nm was read after 24 h of incubation at 35°C to determine the number of Candida. The number of Candida was determined after 24 h of the incubation at 35°C by a spectrophotometer with OD at 630 nm.
Phagocytosis and Killing Assays
Human phagocytes from healthy donors were separated by 6% dextran solution, as previously described (41) . Coincubation of 3 ϫ 10 3 phagocytes/ml with 3 ϫ 10 3 blastospores/ml of C. albicans in PBS with the serial concentrations of ascorbate (10 -40 mM) adjusted to pH 7 at 37°C for 1 h was performed. Then, 100 l of well-mixed solution was isolated and stained with Wright's stain according to the standard protocol. Phagocytic activity was determined by the percentage of phagocytes with Candida blastospores inside to the total phagocyte count at ϫ400 magnification from 100 fields per slide. Concurrently, to determine the phagocyte-killing function, 150 l of the solution was centrifuged to separate phagocytes, then washed twice with PBS, recentrifuged, and filled with 100 l of a nutritionally rich medium (Lysogeny broth; Sigma-Aldrich) to initiate complete cell disruption and the release of intracellular blastospores. The solution was then put in SDA at 35°C for 24 h and counted for fungal colonies (16) . All experiments were performed in triplicate.
Statistical and Survival Analysis
SPSS version 17.0 (SPSS, Chicago, IL) was used for all statistical analyses. Data are presented as mean values and the standard error of the means (means Ϯ SE). Differences among groups of results were examined using one-way ANOVA, followed by Bonferroni analysis. The two-tailed Student's t-test was used to examine the difference of the optical density at 630 nm between Asc and Ampho BϩAsc and also used to demonstrate the difference in serum creatinine between Candida plus CLP and sham. A P value Ͻ0.05 was considered statistically significant. Survival analyses were evaluated using the log-rank test by observation and recorded every 6 -12 h for the first 72 h after Candida injection or CLP surgery, and then once daily to 7 and 14 days for CLP survival and Candida injection survival, respectively. Mice exhibiting extreme morbidity were euthanized. Some of the mice with the manifestations of the extreme morbidity, such as abnormal breathing patterns or no response to stimuli, were euthanized, and their internal organs were examined for organ histology.
RESULTS
Characteristics of Candida Injection Model
After the injection of different doses of Candida, candidemia presented after all of the selected doses of the injection. Candidemia became undetectable after 3-6 h for low-dose injections (OD 630 nm 0.3 and 0.6) ( Fig. 2A, inset) and then reappeared (Fig. 2B) . Despite the disappearance of Candida from the blood after 6 h and 24 h after injection with a dose of OD 630 nm 0.3, Candida was present in all measured organs (Fig. 2C) . At 6 h after injection, Candida was predominantly presented in the lung and kidney 59 Ϯ 5 and 43 Ϯ 12 CFU·ml Ϫ1 ·mg
Ϫ1
, respectively. The presence of Candida was predominant in the liver and spleen, 20 Ϯ 7 and 11 Ϯ 3 CFU·ml Ϫ1 ·mg
, respectively (Fig. 2C) . At 24 h, the organ in which Candida was most presented was the kidney, at 18 Ϯ 7 CFU·ml Ϫ1 ·mg Ϫ1 (Fig. 2C) . These results indicated that Candida infection remained in tissues despite clearance from the blood after this inoculation dose. The candidemia clearance after the inoculation dose of OD 630 nm 0.3 (2 ϫ 10 5 CFU/ml) facilitated the identification of this dose level for the further experimental study of the reactivation of candidiasis.
Characteristics of a Model of Reappearance of Candidemia During Sepsis (CandidaϩCLP)
The goal of a superimposed Candida infection in a sepsis model is to have reappearance of Candida, so as to mimic Candida infection as it occurs after sepsis in humans. Therefore, the reappearance of candidemia was demonstrated. Candidemia spontaneously reappeared from the 4th day after Candida injection alone (Fig. 2B ), but reappeared as early as 6 h after CandidaϩCLP (Fig. 3A) , ϳ93 h earlier. Moreover, candidemia in CandidaϩCLP increased very rapidly from 34 Ϯ 16 CFU/ml at 3 h to 2,143 Ϯ 434 CFU/ml at 24 h after CLP (Fig. 3A) . In contrast, Candida injection alone without CLP showed a delayed and more modest increase in candidemia from 15 Ϯ 10 CFU/ml at day 4 to 1,650 Ϯ 897 CFU/ml at day 7 after injection ( Fig. 2B ). Of note, CLP alone did not produce candidemia at 24 h after CLP (Fig. 3A) and at 7 days (data not shown). Moreover, C. albicans could not be detected by culture (see METHODS) of cecal contents and gastrointestinal tissues of normal and septic mice. Sepsis from CLP without Candida, coupled with postsurgery treatment, showed a survival rate of 73% (11 of 15 mice) at day 7 (NSSϩCLP), indicating a modest severity of sepsis in our CLP model (Fig.  3B ). The addition of Candida infection before sepsis (CandidaϩCLP) produced 100% mortality at 5 days (Fig. 3B) . Moreover, mice with CandidaϩCLP died rapidly, with Ͼ50% mortality within 1 day and Ͼ67% mortality within 2 days (Fig.  3B) . Rapid mortality in the CandidaϩCLP model is likely due to the severity of sepsis. Compared with controls, within the first 24-h CandidaϩCLP mice had higher cytokines and more pronounced neutropenia than CLP alone (Fig. 3, C-G) , as well as higher fungal burden (Fig. 3A) . Limited leukocytosis and/or rapid neutropenia could be factors in the severity of CandidaϩCLP. In contrast, germ tube production in septic serum was lower than in normal serum (Fig. 3H) . High blood Candida levels in CLP mice (Fig. 3A) , despite less Candida growth in vitro with septic serum, is consistent with an immunologic cell role in the control of candidemia. CandidaϩCLP mice at 3 days after injection showed multiple Candida pseudohyphae lesions on the heart, renal glomeruli, and renal interstitium (Fig. 4) . These findings are consistent with disseminated candidiasis. The reappearance of Candida from internal sources in the CandidaϩCLP mice resembles human sepsis in terms of the reactivation of latent Candida, although from different sources of Candida (21, 50) . Subsequently, we used the CandidaϩCLP model for further studies due to the Candida reactivation property of the model.
The In Vitro Synergistic Effect of Amphotericin B with Ascorbate and In Vivo Ascorbate Concentrations
We used the CandidaϩCLP model to test the synergistic properties of Ampho B and ascorbate, beginning with in vitro experiments. The Ampho B concentration was selected at 10 times lower than the minimal inhibitory concentration (MIC), and incubations were performed with different pharmacological ascorbate concentrations. The Ampho B concentration was chosen such that no fungicidal effect was predicted with its use alone. Also, a very low dose of Ampho B could reduce nephrotoxicity in vivo. Ascorbate concentrations were chosen to reflect those measured in humans after intravenous administration (66, 67) . As predicted, neither low-dose Ampho B (125 ng/ml) alone nor ascorbate alone had any effect on Candida growth. Ampho B combined with ascorbate concentrations ranging from 10 to 40 mM demonstrated growth inhibition of ϳ85% (Fig. 5) . Alternatively, there was no synergistic effect of ascorbate at these concentrations with fluconazole at a dose 10 times lower than the MIC (125 ng/ml) (data not shown). It appears that the synergistic effects of high-dose ascorbate may be limited to only specific antifungal drugs.
Subsequently, ascorbate concentration at or above 10 mM was chosen as the target level of serum ascorbate for further experiments. We take advantage of renal dysfunction in the CandidaϩCLP model to maintain serum ascorbate (Fig. 6A) . While ascorbate is rapidly cleared in mice without renal insufficiency, ascorbate concentrations are maintained at or above 10 mM for many hours in CandidaϩCLP mice with ascorbate injection at 12 h and 18 h after surgery (Fig. 6B) . Ascorbate injections administered prior to 12 h post-CLP were cleared more rapidly (data not shown). In addition, the treatment of patients is usually performed after the onset of the diseases, which is similar to the delayed treatment in the mouse model. For these reasons, we conducted experiments with treatment beginning 12 h after sepsis to test the synergy of pharmacologic ascorbate with low-dose amphotericin B.
Low-Dose Amphotericin B Plus Pharmacologic Ascorbate In Vivo: Effects in a Model of Reappearance of Candidemia During Sepsis (CandidaϩCLP Model)
The objective of these experiments was to test the therapeutic effects of low-dose Ampho B (0.1 mg·kg Ϫ1 ·dose
Ϫ1
, which is 10 times lower than the MIC) combined with pharmacological ascorbate. As controls, deoxycholate alone (NSSϩDe-cholate), pharmacologic ascorbate with deoxycholate (AscϩDe-cholate), low-dose Ampho B alone (NSSϩAmpho B 0.1 MK), and full-dose Ampho B alone (NSSϩAmpho B 1 MK) showed no survival benefit at 7 days (Fig. 7, A and B) . Only ascorbate combined with low-dose Ampho B (AscϩAmpho B 0.1 MK) improved the 7-day survival, from 9% (2/22) to 54% (12/22) (Fig. 7B) . It is both notable and interesting that full-dose Ampho B alone improved the survival in days 1 and 2, but was reversed on day 3, leading to high mortality and a low 7-day survival rate (Fig. 7B) . In bacterial sepsis alone without Candida injection (CLP), there was a tendency toward improved sepsis survival in the ascorbate administration group, but the improvement was not statistically significant (AscϩDe-cholate vs. NSSϩDecholate) (Fig. 7C) . Although Ampho B administration in CLP mice did not noticeably worsen the severity of sepsis (NSSϩDe-cholate vs. NSSϩAmpho B 1 MK), it seemed to neutralize the potential benefit of ascorbate administration (AscϩAmpho B) (Fig. 7C) . To determine the microorganism loads, blood and peritoneal fluid were collected at 24 h for Candida and bacterial cultures. As expected, candidemia and peritoneal Candida was lower with low-dose Ampho B plus ascorbate, but not with low-dose Ampho B alone (Fig. 8,  A and B) , consistent with the in vitro data (Fig. 5) . However, bacterial burden was not different between groups (data not shown). In addition, we evaluated sepsis severity in the CandidaϩCLP model at 24 h, based on the following serum markers: Scr for renal function, ALT for liver function, and cytokines for immune responsiveness. We also obtained histopathology data of the kidney, spleen, and heart (Fig. 9) . Low-dose Ampho B combined with pharmacological ascorbate attenuated organ injury: kidney injury as determined by Scr (Fig. 8C ) and renal histopathology (Fig. 9H) , liver injury as measured by ALT (Fig. 8D) , and spleen injury as evaluated by vacuole-like lesions in the white pulp of the spleen (Fig. 9I) . Moreover, there was cardiac vacuolization in some mice re- ceiving low-dose Ampho B treatment alone, but not in mice with the combined treatment (Fig. 9G) . Ampho B combined with pharmacological ascorbate reduced IL-6, TNF-␣, and IL-10, but not IL-17 (Fig. 8, E-H ).
Higher Ascorbate Concentration Improved Phagocytosis and Intracellular Killing of Candida by Human Phagocytic Cells
Effective phagocytosis and phagocyte killing are mechanisms for the control of candidiasis, especially in the setting of neutropenia (32) . The phagocyte killing depends on oxidative stress production, which might be associated with ascorbate (61) . We tested the ability of human phagocytic cells to phagocytize and kill Candida, in the presence of different ascorbate concentrations. Phagocytic activity was enhanced with pharmacological ascorbate concentrations of 30 and 40 mM (Fig. 10A) , and Candida killing activity improved at concentrations of 20 and 40 mM (Fig. 10B) .
DISCUSSION
Prior mouse models of Candida used Candida injection after sepsis (9) , but this may not be the ideal method to mimic reactivation of candidemia. In this study, we injected Candida before sepsis, which was induced by CLP surgery 6 h after Candida injection. We demonstrated that sepsis reactivated candidemia, resembling the alteration of intrinsic Candida microbiota in patients with candidiasis (50). We found more severe injuries and a much higher mortality rate in CandidaϩCLP, compared with CLP alone. Using this model, we were able to investigate a new treatment modality and the combination of pharmacological ascorbate with low-dose amphotericin B (Ampho B). This combination improved survival and attenuated disease severity, compared with the use of either modality alone.
The severity of intravenous Candida albicans infection depends on the injected doses and the properties of C. albicans used in different studies (36, 56) . With high-dose Candida injection, candidemia persisted at all time points. As for lowdose Candida injection, mice cleared up candidemia very rapidly within the first 24 h after injection, with no spontaneous reappearance until after 4 days. Even with rapid clearance of candidemia in the low-dose model, tissue Candida persisted in the lung, kidney, and liver, consistent with other reports (36, 66) . For these reasons, low-dose injections seemed to suitably mimic the immunosuppression phase, despite the more rapid natural course in mice, compared with human patients with sepsis. It is interesting to note that Candida injection alone without CLP did not cause renal injury at 24 h after injection, as measured by serum creatinine (Scr) (Figs. 8C and 9H) , despite Candida being detected in the kidney at 24 h (Fig. 2C) .
Decreasing the time interval needed for Candida reappearance would improve the experimental model of sepsis immunosuppression. Candida reappeared as early as 6 h after sepsis initiation in a model of reappearance of candidemia during sepsis (Fig. 3A) . In comparison, more than 4 days were needed in nonseptic mice for Candida reappearance (Fig. 2B) . Several sources of Candida reactivation were demonstrated in several organs (Fig. 2C) for mice in the CandidaϩCLP model, which was different from the translocation across the gut mucosa in patients with superimposed candidiasis (14) . However, the reactivation of the existing internal sources of Candida may more closely resemble the human condition, compared with other current models. Sepsis immunosuppression is initially defined as a condition in which patients or experimental animals are susceptible to opportunistic infection in sepsis patients (40, 55) . There are at least two hypotheses related to the sepsis-immunosuppressive phase. The serial theory states that immunosuppression takes place after the hyperinflammatory phase. The parallel theory states that immunosuppression is concomitant with hyperinflammation (3, 52) . Generally, immune compromise after sepsis can be manifested by the reactivation of endogenous infections, such as cytomegalovirus, herpes virus, mycobacteria, and candidosis. We used candidemia reactivation as a marker of sepsis immunosuppression. It was necessary to inject Candida to be able to study its reactivation as part of sepsis immunosuppression. Without prior Candida injection, we could not identify C. albicans by culture methodology in gastrointestinal tissue and contents, the natural reservoir of Candida (14) , from either normal or septic mice. Several explanations for this failure to identify C. albicans are possible, including 1) conventional culturing methods may be insufficient to detect Candida as part of normal mouse flora; 2) Candida may not be part of normal mouse flora; or 3) the presence of Candida may be dependent on mouse environment or strain. More sensitive detection methods and/or longer observation times after sepsis (60) might be necessary to demonstrate spontaneous candidemia after sepsis alone. Nevertheless, the reactivation of candidemia in CandidaϩCLP was very rapid, within hours after sepsis, compared with days or weeks in patients in the intensive care unit. This difference might, at least in part, be due to more focused and appropriate treatments and life support systems for patients, a notable absence in experimental studies using mice.
The Candida injection changed a modest severity of CLP model with a 30% mortality rate into more severe injury with a 100% mortality rate (Fig. 3B) . A number of factors could be responsible. The germ tube findings that we report here show that the serum of sepsis mice was less effective than normal mouse serum as for fungal growth, despite an exponential increase in Candida in sepsis. This finding suggests that changes in immune response elements could be responsible for accelerated candidemia in CandidaϩCLP septic mice. One contributing factor may be a decreased neutrophil response in CandidaϩCLP compared with CLP alone, consistent with the neutrophil depletion occurring more rapidly when sepsis is combined with candidemia (31, 32) . Rapid neutrophil depletion in CandidaϩCLP might be due to the higher sepsis severity, which leads to the higher rate of neutrophil apoptosis, as previously mentioned (18) . Another factor may be associated with IL-17 responsiveness in CandidaϩCLP mice, as IL-17 is a cytokine responsible for the fungal infection (25, 26) . While CandidaϩCLP mice had an increase in IL-17 compared with CLP mice, the increase may have been insufficient for host protection. IL-17 was the only cytokine, among others we tested, with a similar level at 24 h in CandidaϩCLP, compared with CLP alone. Moreover, IL-17 was the earliest cytokine to increase as early as 3 h after CandidaϩCLP, but IL-17 did not increase in CLP alone. This characteristic suggested the importance of IL-17 in controlling the severity of sepsis in the CandidaϩCLP model. We propose that IL-17 synthesis in CandidaϩCLP was more strongly stimulated by both bacterial and fungal infection (25, 26) . The dual importance of IL-17 in both bacterial and fungal infection was previously published (19, 20, 25, 28) . Still another contributing factor of high mortality in CandidaϩCLP mice could be injury to the spleen. In this study, we found groups of apoptotic/ necrotic cells in the white pulp of the spleen, previously described as a "vacuole-like area", were more prominent in CandidaϩCLP spleens, consistent with the description in severe sepsis (44) . Apoptosis of immune cells, especially apoptosis in the spleen as reported in patients with sepsis (24) and mouse models of sepsis (34, 35, 44) , was hypothesized to be one of the responsible factors for the immunosuppression and more severe injury in sepsis. The severe destruction of the spleen might be an additional contributing factor to the immunosuppression observed in the CandidaϩCLP model.
In animals and humans, concentrations of ascorbate (vitamin C) are normally tightly controlled when it is ingested orally, via transporter saturation (45) (46) (47) . In humans, intestinal transporters saturate at doses above 200 mg, with decreased bioavailability. Tissue transporters saturate when ingested doses are above 100 mg. Likewise, the renal reabsorptive ascorbate transporter saturates at doses above 100 mg, with urinary excretion of unabsorbed ascorbate. Together, these mechanisms produce orchestrated ascorbate concentrations. When ascorbate is administered either intraperitoneally in animals or intravenously in animals or humans, tight control mechanisms are transiently saturated, until renal excretion restores homeostasis. With parenteral administration of pharmacological doses of ascorbate, plasma concentrations can reach 500 times those possible with oral administration (47) . Only these pharmacological concentrations produce hydrogen peroxide in the extracellular fluid, which serves as a pro-drug for the formation of reactive oxygen species that are toxic to cancer cells, but harmless to normal tissues (4, 7, 23) . It has been postulated that ROS formed from pharmacological ascorbate could also be harmful to bacteria (6) . Lower doses of pharmacological ascorbate have effects that attenuate the severity of sepsis (1, 2, 58, 63-65, 67) that are not bactericidal.
Our findings showed that while pharmacological ascorbate alone was ineffective for candidemia, pharmacological ascorbate combined with Ampho B, even when the latter was reduced to 10 times lower than the MIC, was more effective than Ampho B alone. Furthermore, full-dose Ampho B showed minimal survival at 7 days in the Candida CLP model, compared with more than 50% survival at 7 days using pharmacological ascorbate with low-dose Ampho B. In vitro, for maximum synergy with low-dose Ampho B, 10 mM ascorbate was sufficient (Fig. 5) . This concentration was not only easily achieved in mice but also achieved easily and safely in humans (23) . Synergy between pharmacological ascorbate and Ampho B may be a consequence of each having separate actions on Candida membranes. Ampho B is a pore-forming agent that destabilizes the Candida membrane. Reactive oxygen species generated by pharmacological ascorbate from hydrogen peroxide, could also act independently to destabilize Candida membranes. In addition, hydrogen peroxide may also diffuse into Candida, with the subsequent formation of internal reactive oxygen species leading to internal membrane or protein damage. These potential actions of pharmacological ascorbate are independent of Ampho B, and synergy is reasonably predictable. Additional independent effects of ascorbate on neutrophils, phagocytosis, and killing could also contribute to the benefits of pharmacological ascorbate (15, 27, 53, 61) .
Because Ampho B is nephrotoxic, lower-dose regimens are preferable. Pharmacological ascorbate was permissive for lower dosing of Ampho B in the CandidaϩCLP model. The CLP model induces renal insufficiency, such that only two doses of intravenous ascorbate as the delayed treatment were sufficient. In contrast, most of the successful sepsis treatments in mouse models need to be administered at the onset or the early phase of sepsis (10, 12, 13, (33) (34) (35) .
A concern relating to this model is whether or not additional nephrotoxicity is induced by pharmacologic ascorbate. In the setting of renal insufficiency, intrarenal oxalate formation and crystallization are concerns with pharmacological ascorbate. Oxalic acid, an end product of ascorbate metabolism, can crystallize as calcium oxalate in urine and renal interstitial tissues. In CandidaϩCLP mice treated with ascorbate, we did not find any crystal deposits in kidney histology, after 1 day and from autopsy (data not shown). We also found that serum creatinine was lower in mice treated with pharmacological ascorbate combined with low-dose Ampho B, compared with Ampho B alone. Moreover, we demonstrated that ascorbate injection in CandidaϩCLP did not alter the kidney function. On the other hand, full-dose Ampho B improved the mortality rate at day 2 of survival but not at day 7 of survival, a finding that suggests its toxicity in full-dose treatment (Fig. 6B) . The findings from the combined treatment group demonstrate that the treatment effects of adding pharmacological ascorbate were beneficial for renal function. Another concern involved the limitations of mouse models and whether or not they are able to sufficiently represent human patient conditions and responses. The debate on this topic is still ongoing (54, 57) . Nevertheless, we postulated that our two-hit models are more complex and might more accurately mimic the patient's conditions. However, validation in patients with reciprocal sepsis condition is required.
Perspectives and Significance
In our new mouse model demonstrating an immunosuppressive phase with Candida reappearance, a synergistic effect of pharmacological ascorbate with low-dose Ampho B was demonstrated in vitro and in vivo, without apparent toxicity. Taken together, the data provide a proof of concept for pharmacological ascorbate as an adjuvant for antifungal treatment. Pharmacological ascorbate is inexpensive and can be easily available. Pharmacological ascorbate in combination with existing antifungals may indicate the use of lower doses with reduced toxicity.
